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Abstract 
The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values. While this 
is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible, or 
mechanism-based inhibitors (MBI). IC50 values of MBI are time-dependent, causing serious problems 
when aiming at ranking different compounds with respect to their inhibitory potential. As a 
consequence, most studies and ranking schemes related to MBI rely on the inhibition constant (KI) and 
the rate of enzyme inactivation (kinact) rather than on IC50 values. In this article we derive a novel 
relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of 
inhibition. This allows for direct estimation of KI and kinact values from time-dependent IC50 values, 
even without the need of additional pre-incubation experiments. The application of this approach is 
illustrated using a fluorimetric assay to access the drug-drug interaction potential associated with new 
chemical entities. The approach can easily be implemented using standard software tools (e.g., XLfit) 
and may also be suitable for applications where mechanism-based inhibition is a desired mode of 
actions, e.g., at particular pharmacological drug targets.  
 
 
Keywords: irreversible inhibition, time-dependent IC50 values, Cheng-Prusoff relation 
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Introduction 
Characterizing the potential of irreversible inactivation of an enzyme by a drug is useful, e.g., when 
aiming at avoiding undesirable inhibition of metabolising enzymes in the body (e.g., cytochrome P450 
enzyme inhibition), or when aiming at efficiently inhibiting target enzymes (e.g., in cancer therapy). 
The potential of enzyme inhibition is frequently quantified in terms of IC50 values, characterizing the 
degree to which the enzyme activity is inhibited, which are then used, e.g., for ranking of new chemical 
entities in terms of their inhibitory potency.  
Inhibition of cytochrome P450 enzymes is a principle mechanism for drug-drug interactions which may 
cause severe complications in the clinics (Kalgutkar et al., 2007). It is the underlying mechanism of 
some of the most notable drug-drug interactions of greatest magnitude (Venkatakrishnan et al., 2003), 
e.g. paroxetine and CYP2D6 (Bertelsen et al., 2003), clarithromycin and CYP3A (Mayhew et al., 2000), 
furanocoumarins and CYP3A (Greenblatt et al., 2003). In order to access the drug-drug interaction risks 
associated with new chemical entities (NCE), in vitro studies—particularly those utilizing liver 
microsomes, hepatocytes or recombinant CYPs—are being applied (Di et al., 2007 , Bachmann et al., 
2006, Venkatakrishnan et al., 2003). For a thorough discussion of the different approaches see 
Bachmann et al., 2006; Tucker et al, 2001; Zlokarnik et al., 2005. One of the assays being employed is a 
microtiter-plate assay that uses cDNA expressed human hepatic CYPs and fluorimetric substrates 
(Crespi et al., 1997). This assay allows a quick estimation of IC50 values, which then can be used to 
rank compounds according to their DDI potential (Krippendorff et al., 2007, Turpeinen et al., 
2006). However, in order to predict the risk of a particular NCE for drug-drug interactions in the clinics, 
assays based on liver microsomes and drug substrates are much preferred—especially in case of CYP 
3A4 for which multiple binding sites have been described (Scott and Halpert, 2005).  
Mechanism-based inhibition can also be a desirable property, e.g. when targeting enzymes in cancer 
therapy (Bruno and Njar, 2007), inhibiting prastatic acid phosphatases (Myers and Widlanski 1993) or 
zinc proteases (Kim and Mobashery 2001).  
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The existing types of enzyme inhibition can be roughly divided into reversible and irreversible 
inhibition. While much research has been conducted to understand reversible interactions, much less is 
known for irreversible or mechanism based inhibition (Obach et al., 2005, 2006, 2007, Venkatakrishnan 
et al., 2003). Although simple and fast approaches based on the fluorimetric assay to identify 
mechanism based inhibitors have been described in the literature (Cheng and Prusoff, 1973, He et al., 
1998) the determination of the kinetic parameters of inactivation has been left to more complex study 
designs employing different pre-incubation schemes (Naritomi et al., 2004). In case of reversible 
inhibition conversions from IC50 into the KI value are usually performed using the Cheng-Prusoff 
equations (Cheng and Prusoff 1973). For mechanism-based inhibition assays, in additional to the KI 
value, a second parameter kinact accounting for the irreversible inhibition has to be taken into account. 
This parameter is related to the time-dependent decrease of IC50 values for irreversible inhibition (Yan 
et al., 2002). In this situation, the Cheng-Prusoff equation results in erroneous predictions.  
 
The objective of this paper is to estimate the kinetic parameters KI and kinact directly from time-
dependent IC50 measurements without the need to perform additional pre-incubation experiments. To 
this end, we develop a general relation between IC50, KI and kinact for mechanism-based inhibitors. It is 
based on a mathematical model of the experimental setup for the determination of the IC50. The 
assumptions, under which the general relation is valid, reflect the typical experimental conditions of the 
in vitro assays. We illustrate this new approach using a fluorimetric assay where time-dependent IC50 
values can easily be obtained by continuously measuring the plate in the fluorescence reader. Results are 
given for CYP450 iso-enzymes 1A2 and 3A4, i.e., enzymes with well-defined and complex binding 
characteristics, respectively. Estimated values for KI and kinact are generally in good agreement with 
experimental data from literature. 
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Material and Methods 
2.1  Materials 
Baculovirus/insect cell expressed human CYP1A2 and CYP3A4 microsomes (Supersomes), 3-Cyano-7-
Ethoxycoumarin (CEC), 7-Benzyloxy-trifluoromethylcoumarin (BFC), cofactors, glucose-6-phosphate 
dehydrogenase and potassium phosphate buffer were obtained from GENTEST / BD Biosciences 
(Woburn, MA). Test chemicals and their suppliers were as follows: Raloxifen and Ethinylestradiol were 
synthesized in the laboratories of Bayer Schering Pharma AG, Berlin, Germany. All other test 
compounds were purchased from SIGMA-Aldrich, Munich, Germany. 
2.1.1  Fluorimetric Enzyme Inhibition Assay 
Incubations were conducted in black 96-well microtiter plates (Greiner Bio-One GmbH, Frickenhausen, 
Germany) based on the method described by GENTEST with slight modifications as described in 
summary below. All incubations were performed in either 50 mM (CYP 1A2) or 200 mM (CYP 3A4) 
potassium phosphate buffer at pH 7.4 containing 8.1 µM NADP+, 0.41 mM MgCl2, 0.4 mM glucose-6-
phosphate and 0.2 IU/ml glucose-6-phosphate dehydrogenase. Final concentrations of cytochrome P450 
enzymes and substrates were 2.5 nM CYP1A2, 5 nM CYP3A4, 5 µM CEC and 50 µM BFC. All test 
compounds were dissolved in acetonitrile and serially diluted (1:3) to six final concentrations ranging 
from 0.041 to 10 µM keeping the final concentration of acetonitrile to 2% in all incubations. The plate 
with buffer, test compounds and cofactors was pre-warmed at 37 °C and the reaction was started by 
adding pre-warmed (37 °C) enzyme/substrate mixture. Fluorescence in each well was measured using a 
PerkinElmer Victor3 multilable counter with temperature control set to 37 °C. Instead of using end-
point measurements CYP activity was determined at intervals of two minutes up to 30 min after start of 
reaction using excitation/emission wavelength of 410/460 nm and 410/530 nm for CYP1A2 and 
CYP3A4, respectively. Usually, measurements at very early time points are more difficult to obtain (and 
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therefore often more error-prone) due to the experimental setup. Since early measurements are not 
necessarily required for our proposed approach, measurements were taken starting from 5min. For 
analysis fluorescence data were exported to Excel and IC50s at various time-points were determined by 
fitting the experimental data to a sigmoidal dose-response model using XLfit (IDBS, Guilford U.K.).  
2.2 Models of enzyme inhibition 
Experimentally, the inhibitory potential of an enzyme inhibitor is determined by measuring the decrease 
in metabolite formation by the enzyme in the presence of the inhibitor—measured using a fluorimetric 
or liquid chromatography-mass spectrometry (LC-MC) assays.  
The IC50 value is typically defined as concentration of the inhibitor, at which the velocity of product 
formation is half the velocity without inhibitor (Cheng and Prusoff, 1973). For reversible inhibition, this 
is identical to the inhibitor concentration that decreases the metabolite concentration by 50%.  
In the sequel we will present a theoretical approach that allows for determining the IC50 in a way that 
exactly matches the experimental setup of the in vitro assay and defines the IC50 in terms of the model-
theoretical analogue of the fluorescent product concentration. As a special case, we regain the well-
known Cheng-Prusoff equations, if we impose additional assumptions. These additional assumptions are 
typically satisfied for reversible inhibition; however, they are clearly violated for the important class of 
mechanism-based inhibitors. 
In the following we have chosen the two examples of competitive inhibition and mechanism-based 
inhibition to derive a mathematical description of time-dependent CYP inhibition. This allows for 
illustrating the common parts as well as the differences between our approach and the Cheng-Prusoff 
approach.  
 
Product formation without inhibition.   In the absence of any inhibitor, the product formation by a 
catalytic enzyme reaction typically comprises the following reaction steps:  
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E + S k1S← →  
k−1S
E : S kcatS →   E + P  (1) 
 
 
The velocity of product formation is approximated by Michaelis-Menten kinetics:  
 
V0(t) =
d
dt
P0(t) =
Vmax ⋅ S
KM + S
,  (2) 
 
 
where Vmax = kcatS * Ecat denotes the maximal velocity of product formation defined in terms of the 
functional catalytic enzyme concentration Ecat (here identical to the total enzyme concentration), and KM 
denotes the substrate concentration, at which V0=Vmax/2.  
 
Competitive inhibition.   In the case of competitive inhibition, the inhibitor may form a complex with 
the free enzyme and thus decrease the rate at which the product is catalysed. This is shown in the 
following reaction scheme  
 
E + S k1S← →  
k−1S
E : S kcatS →   E + P  (3) 
.:
1
1 IEIE
k
k
−
→←+
 
 
The resulting velocity of product formation is then given by  
 
VI t( )=
d
dt
PI (t) =
Vmax ⋅ S
KM 1+
I
K i
 
 
 
 
 
 + S
, (4) 
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where in addition to Eq. (2) the parameter Ki = k−1/k1 denotes the dissociation constant of the inhibitor-
enzyme complex.  
 
We remark that for the above two models, the maximal velocity Vmax does not change over time, since 
the underlying functional catalytic enzyme concentration is constant in time. This condition, however, is 
violated for the following type of inhibition.  
 
Mechanism-based inhibition.   This form of inhibition involves in addition to the competitive 
inhibition a reaction that irreversibly transforms the inhibitor-enzyme complex into an “inactive" form, 
denoted by E:I*. The corresponding reaction scheme is given by 
 
E + S k1S← →  
k−1S
E : S kcatS →   E + P  (5) 
E + I k1← →  
k−1
E : I kinact →   E : I*, 
 
 
where kinact describes the rate at which inhibitor-enzyme complex is irreversibly transformed into E:I*. 
The resulting equation for product formation is given by  
 
VI (t) =
d
dt
PI (t) =
Vmax (t) ⋅ S
KM 1+
I
K I
 
 
 
 
 
 + S
, (6) 
 
where due to the irreversible formation of E:I*, the functional catalytic enzyme concentration Ecat(t) 
does decrease in time, resulting in a time-dependent maximal velocity Vmax (t) = kcat ⋅ Ecat (t) . The 
maximal rate of inactivation is defined by the product of kinact and the active enzyme concentration. The 
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parameter KI   is the inhibitor concentration that results in half the maximal rate (Mayhew et al., 2000). A 
detailed description of the relation between KI and Ki can be found in (Mayhew et al., 2000).  
The resulting time-dependent decrease in functional catalytic enzyme requires establishing an additional 
evolution equation for Ecat(t). To do so, we note that Etot = Ecat+E:I*(t), where Etot denotes the total 
enzyme concentration in the system (that is assumed to be constant). Under steady state conditions, the 
concentration of the enzyme-inhibitor complex E:I(t) over time satisfies 
 
E : I(t) = I
K I 1+
S
KM
 
 
 
 
 
 + I
⋅ Ecat (t) ,  (7) 
 
from which we may derive the required equation: Since Ecat(t)=Etot−E:I*(t) and  d/dt Etot=0, it is 
d
dt
E:I∗ t( )= kinact ⋅ E:I t( ), which combined with Eq. (7) results in  
 
d
dt
E cat (t) = −kinact ⋅ηI ⋅ E cat , (8) 
 
with initial condition Ecat(0)=Etot and  
 
ηI =
I
K I 1+
S
KM
 
 
 
 
 
 + I
. (9) 
 
To highlight the dependence of Vmax(t) on Ecat in Eq. (6) , we rewrite (6) as:  
 
d
dt
PI (t) =
kcat ⋅ E cat (t) ⋅ S
KM 1+
I
K I
 
 
 
 
 
 + S
,  (10) 
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Control and the definition of IC50.   In many experimental approaches to determine IC50 values, the 
increase in fluorescent product concentration is measured. Unlike many other theoretical approaches, 
our definition of the IC50 directly builds upon the fluorescent product concentration P(t) at time t. Let 
us define the control, a function of time t and inhibitor concentration I, as  
 
,)(
)(),(
0 tP
tPItcontrol I=   (11) 
 
where PI(t) and P0(t) denote the concentration of product at time t in the presence of an inhibitor (at 
concentration I), respectively, in the absence of any inhibitor. Based on the control, the IC50 value is 
then defined as the inhibitor concentration at which the product concentration is half the concentration 
of the system without inhibitor, hence  
 
).(
2
1)(
2
1)50,( 050 tPtPICtcontrol IC =⇒=   (12) 
 
This characterization is used to determine the relation between IC50, KI and kinact. The IC50 may 
depend on time, as is the case, e.g., for mechanism-based inhibition. We note that the general solution to 
Eqs. (2) and (4) is given by  
 
PI (t) = P(0) + VI (τ)dτ
0
t
∫ , (13) 
 
with possibly time-varying velocities of product formation VI(t) and V0(t) in the presence and  absence 
of the inhibitor, respectively. Under the addition assumptions that V0(t) and VI(t) are constant in time, 
and P0(0)=PI(0)=0, Eq. (11) simplifies to  
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,
2
1
)(
)(),( 050
0
VV
tV
tVItcontrol ICI =⇒=   (14) 
 
which is the starting point for the derivation of the well-known Cheng-Prusoff relation between IC50 
and KI. These additional assumptions (V0(t) and VI(t) are constant in time and P0(0)=PI(0)=0) are 
satisfied for reversible inhibitors (see (Cheng and Prusoff, 1973) for other types of reversible inhibitors), 
thereby including competitive inhibitors; however they are not satisfied for mechanism-based inhibitors, 
as can be seen from eq. (6). This clearly shows that the Cheng-Prusoff approach must necessarily fail 
when aiming at mechanism-based inhibition.  
2.3  Cheng-Prusoff equation for competitive inhibition 
Usually, the in vitro assay is set up in such a way that (A1) the amount of substrate does not change 
significantly during the performance of the assay, i.e., realized by choosing S >> Etot, (A2) the amount 
of inhibitor does not change significantly in time, and (A3) the amount of catalytically active enzyme is 
constant in time. Under these assumptions, the resulting product formation velocities in Eqs. (2) and (1) 
are constant in time. Hence, assuming zero initial product concentration, i.e., P0(0)=PI(0)=0 (which is 
realized by subtracting background fluorescence) we obtain  
 
P0(t) =
Vmax ⋅ S
KM + S
⋅ t, and   PI (t) =
Vmax ⋅ S
KM 1+
I
K i
 
 
 
 
 
 + S
⋅ t .     (15) 
 
Finally, the IC50 is determined by  
 
1
2
=
PIC 50(t)
P0(t)
=
KM + S
KM 1+
IC50
K i
 
 
 
 
 
 + S
, (16) 
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which yields the well known Cheng-Prusoff equation for competitive inhibition (Cheng and Prusoff, 
1973): 
 
K i =
KM
KM + S
⋅ IC50.     (17) 
 
This shows the consistency of our approach to the well-established Cheng-Prusoff equation for 
competitive inhibition. Equations for other types of reversible inhibition can be derived in the same 
manner; for details see (Cheng and Prusoff, 1973).  
2.4  Central relation between time-dependent IC50(t) values and the parameters KI 
and kinact 
For mechanism-based inhibition, we assume that (A1) the amount of substrate does not change 
significantly during the performance of the assay, and (A2) the amount of inhibitor does not change 
significantly in time. We do not assume that the amount of catalytically active enzyme is constant in 
time. Under these assumptions, we may explicitly solve for the fate of the catalytically active enzyme 
Ecat in Eq. (8), since under these two assumptions, ηI in (9) is constant in time:  
 
E cat (t) = E cat (0) ⋅ e−kinact ⋅η I ⋅ t . (18) 
 
Inserting Ecat(t) into Eq. (10) results in:  
 
d
dt
PI (t) =
kcat ⋅ E cat (0) ⋅ e−kinact ⋅η I ⋅ t ⋅ S
KM 1+
I
K I
 
 
 
 
 
 + S
.    (19) 
 
Solving (19) with PI(0)=0 yields  
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PI (t) =
Vmax ⋅ S
KM 1+
I
K I
 
 
 
 
 
 + S
e−kinact ⋅η I ⋅τdτ
0
t
∫
=
Vmax ⋅ S
KM 1+
I
K I
 
 
 
 
 
 + S
1− e−kinact ⋅η I ⋅ t
kinact ⋅ηI
 
 
 
 
 
 .
 (20) 
 
In order to determine the IC50(t) we compute  
 
PIC 50(t) =
Vmax ⋅ S
KM 1+
IC50(t)
K I
 
 
 
 
 
 + S
1− e−kinact ⋅η IC 50 ⋅ t
kinact ⋅ηIC 50
 
 
 
 
 
 . (21) 
 
with  ηIC50 defined by (9) with I=IC50. Exploiting Eq. (12) we obtain  
 
1
2
=
PIC 50(t)
P0(t)
=
KM + S
KM 1+
IC50
K I
 
 
 
 
 
 + S
⋅
1
t
⋅
1− e−kinact ⋅η IC 50 ⋅ t
kinact ⋅ηIC 50
 
 
 
 
 
 . (22) 
 
This finally yields the central relation between time-dependent IC50(t) values and the parameters KI and 
kinact.  
 






−
⋅⋅
−
⋅





+=
⋅⋅−
1221)(50
50
50
tk
e
K
SKtIC
inactIC
tk
M
I
inactIC
η
η
   with ηIC 50 =
IC50(t)
K I 1+
S
KM
 
 
 
 
 
 + IC50(t)
.  (23) 
 
The above equation illustrates that there is a specific curve of IC50 values over time for every 
combination of KI and kinact (see Figure 1). In a typical experimental setup the parameters S, KM, and I, 
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as well as a series of measured time-dependent IC50 values IC50(1), …, IC50(n) at different points in 
time t1,…,tn are known. The task is then to determine KI and kinact,which can done by a least squares fit 
using Eq. (23), e.g., by adding the above equation as a new model in XLfit and computing KI and kinact 
by fitting the right side of the equation to the measured IC50 values. In order to compute the right hand 
side, the input parameterηIC 50  is determined based on the measured IC50 values. As a result, the 
measured IC50 values enter twice in the process of estimating KI and kinact: As an input to the right hand 
side (via ηIC 50 ), and as experimental data to fit the prediction of the model in Eq. (23). As is well 
known, the precision of the estimated parameters typically increases with the number of experimental 
data points (IC50 values) available. Therefore, using the proposed fluorimetric assay, the precision of KI 
and kinact estimation can be increased by increasing the frequency of fluorescence readouts. Figure 2 
shows the complete process of determination of KI and kinact. A step-by-step tutorial for realization in 
XLfit can be found online in the supplement to this paper. 
 
Solving Eq. (23) for KI, we nicely see the analogy to the original Cheng-Prusoff equation:  
KI =
KM
KM + S
 
 
 
 
 
 ⋅ IC50(t) ⋅C kinact , t,ηIC 50( ), (24) 
 
where the factor C depends on kinact, time, and ηIC50:  
 
C kinact ,t,ηIC 50( )=
2 − 2e−η IC 50 ⋅kinact ⋅ t
ηIC 50 ⋅ kinact ⋅ t
−1
 
 
 
 
 
 
−1
. (25) 
 
Hence the central relation (23) can be interpreted as a corrected Cheng-Prusoff equation accounting for 
the time dependent loss of the functional catalytic enzyme. In the limit of vanishing kinact, we obtain C=1 
using l’Hopital’s rule, which is consistent with Eq. (17). In previous attempts this factor has never been 
accounted for correctly (e.g., Maurer et al., 2000).  
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Results  
The derived central relation (23) between KI, kinact and the IC50 values was validated in silico by 
generating concentration-time-profiles of the resulting product over 30 minutes using equation (19), see 
Figure 3 (left). Based on these data, theoretical IC50 values were calculated at each minute based on eq. 
(12), and used to validate relation (23). In addition, we show the prediction based on the relation (B3) 
derived in (Maurer et al., 2000). As shown in Figure 3 (right) the herein derived relation is in excellent 
agreement with the theoretical IC50 values. In contrast, the relationship derived by Maurer et al. differs 
substantially from the IC50 values, in particular it predicts negative IC50 values. 
 
The performance of the proposed approach was further evaluated based on fluorimetric assay data of 
seven well-known MBIs for CYP450 isoforms 1A2 and 3A4. All MBI showed the time-dependent 
decrease in IC50 values (see Figure 4). Clearly, the model predictions nicely describe the decrease of 
IC50 values due to mechanism based inhibition for all six inhibitors (see Figure 5). 
To access the accuracy of the estimated parameters of inhibition, a comparison to literature values that 
were obtained in human liver microsomes by use of the Kitz-Wilson or nonlinear regression method is 
provided. Based on the known parameters S and KM, the inhibition parameters KI and kinact have been 
estimated by fitting model (23) to the time dependent IC50 data. In Table 1 the estimated values of KI 
and kinact (based on single fluorimetric assay experiments) are compared to values of KI and kinact 
estimated by classical data analysis methods (based on a series of pre-incubation experiments). As can 
be inferred from Table 1, generally there is a good agreement between our estimates and KI and kinact 
values based on classical data analysis methods. Calculated kinact values were within a maximal 2.5 fold 
error range of a literature value. KI values were also within a 2.5 fold error range, except for 
Ethinylestradiol and Raloxifene.  
Repeated experiments for Verapamil, Furafylline and Ethinylestradiol with different sampling protocols 
were used to access the impact of experimental variability. Model predictions are in good agreement 
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with experimental IC50 values even for small numbers of sampling points (Figure 5). The resulting 
estimates of KI and kinact for different numbers of sampling point can be found Table 1. 
Discussion 
Irreversible inactivation of enzymes by an inhibitor can be both, undesirable when drug metabolising 
enzymes are inhibited (e.g Cytochrome P450 enzymes) or beneficial when drug target enzymes are 
efficiently inhibited. In both cases, knowledge of the parameters of inhibition KI and kinact is useful in 
order to characterize the inhibitory potential. In this article we derive a novel relation to directly 
estimate these two parameters from time-dependent IC50 values without the need of a series of 
measurements with increasing pre-incubation time. The proposed approach is generally applicable to 
experimental assays that provide a series of time-dependent IC50 values.  
The theoretical derivation is tightly coupled to the experimental conduct of the assay, i.e., the derivation 
is only based on assumptions, under which the in vitro experiment is typically performed. Under these 
assumptions, Eq. (23) provides a mathematically founded relation between the time-dependence of IC50 
values and the parameters of inhibition KI and kinact. To the best of our knowledge, it is the first time that 
this key relation has been reported. Previous attempts were based on relating IC50 value directly to 
reaction velocities (Maurer et al, 2000). During the performance of the assays, however, product 
concentrations rather than reaction velocities are measured. Eq. (14) states that considering 
concentrations or reaction velocities is equivalent for reversible inhibition. However, this is not the case 
for mechanism based inhibition. The difference between the two approaches is apparent from quality of 
predictions shown in Figure 3. By definition, the velocity of product formation decreases over time in 
the presence of irreversible inhibitors. Consequently, comparing reaction velocities at a particular time 
is only a snapshot of the inhibition process at that time. However, it does not take into account the 
gradual inactivation process and its accumulated effect up to that time. This gradual decay of the 
product formation velocity over time, however, has to be considered, which is realised in our approach 
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by integrating the velocity over the incubation time, resulting in the term ηIC 50 ⋅ kinact ⋅ t  in the 
denominator of the central relation (23). A characterization solely based on reaction velocities is 
questionable. 
 
In order to access the drug-drug interaction potential of new compounds, in vitro studies utilizing liver 
microsomes, hepatocytes or recombinant CYPs are being applied (Venkatakrishnan et al., 2003, 
Bachmann et al., 2006). We applied our approach in the context of drug-drug interaction because 
experimental data are readily available, and because irreversible inactivation is the underlying 
mechanism of some of the most important drug-drug interactions of greatest magnitude 
(Venkatakrishnan et al., 2003), e.g. paroxetine and CYP2D6 (Bertelsen et al., 2003), clarithromycin and 
CYP3A (Mayhew et al., 2000), furanocoumarins and CYP3A (Greenblatt et al., 2003).  
As reported by Yan et al., 2002 and Naritomi et al., 2004, irreversible CYP inhibition can easily be 
distinguished from reversible inhibition by comparing the time-dependent pattern of IC50 values from 
CYP inhibition experiments. If a fluorimetric assay is used, data for different time points can easily be 
obtained by reading the fluorescence intensity for an individual plate at several points in time without 
stopping the enzymatic reactions. Therefore, estimating IC50 values over time using microtiter plate 
assays is a simple and attractive method to detect irreversible inhibitors (Naritomi et al., 2004). While 
this approach allowed for the detection of mechanism-based inhibition, the herein proposed application 
makes extended use of the same data to also derive KI and kinact values, therefore moving from a simple 
yes/no statement towards a more quantitative assessment of the DDI potential.  
Typically, the experimental determination of KI and kinact values required the performance of additional 
pre-incubation experiments (Venkatakrishnan et al., 2003), whose data are subsequently analyse by use 
of the Kitz-Wilson or Non-linear Regression method (Kitz and Wilson, 1962). The presented method, 
however, allows for the direct estimation of KI and kinact from the set of time-dependent IC50 values.  
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We have analysed the accuracy and reliability of the predictions based on recombinant CYPs and the 
herein proposed approach for various drugs and the cytochrome P450 isoforms 1A2 and 3A4. The 
estimated KI and kinact values compare well to published data except for the KI value of Ethinylestradiol 
and Raloxifene. This might be due to limitations of the fluorimetric assay, such as interference from 
fluorescent inhibitors. In addition, several CYP isoforms may contribute to the formation of the ultimate 
CYP inhibitor. Because the substrates for fluorescent assays are not CYP selective and necessitate the 
use of recombinant single enzyme systems, the inhibitory effect of metabolites generated by one CYP 
on other CYPs cannot be tested (Bell et al., 2008, Cohen et al., 2003). However, despite these problems, 
time-dependent fluorimetric assays are used to study compounds with respect to potency of MBI 
(Atkinson et al., 2005; Ghanbari et al., 2006, Riley et al., 2007). 
  
In order to evaluate the robustness of our approach to experimental variability we estimated KI and kinact 
based on different sampling protocols and repeated experiments for Verapamil, Furafylline and 
Ethinylestradiol. The good agreement between our model predictions and the experimental IC50 values 
shows that the derived relation is capable of predicting time-dependent IC50 values as different as 
shown in Figure 5. 
Estimated KI values varied roughly 2 fold, while kinact values varied to a larger extent (almost 10 fold). 
As expected, this shows the variability of the underlying biological system, which can also be observed 
in the reported literature values (e.g., Furafylline, or Erythromycin). Given the inherent variability of the 
literature values, results are in good agreement with published experimental data (i.e. less than 2.5 fold 
deviation from a literature value).  
 
In summary, the presented approach allows for the direct use of time-dependent IC50 data to estimate 
the kinetic parameters of inactivation (KI, kinact). Streamlining the process of evaluating mechanism-
based enzyme inactivation is of great interest and importance to the drug discovery process. The design 
of new experimental approaches aiming at mechanism-based inhibitors necessitates the knowledge of 
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the relation between time-dependent IC50 values and the underlying parameters of inactivation KI and 
kinact (see, e.g., Berry and Zhao 2008). The herein derived central relation provides the required 
theoretical foundation. We would like to point out that the presented approach will also be very useful 
in cases where mechanism-based inhibition is a desired property, e.g. targeting enzymes in cancer 
therapy (Bruno and Njar, 2007).  
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Legends 
Table 1: Comparison of KI and kinact values calculated by the herein proposed method and 
literature data. For each compound, a potential range of data for KI (here 0-30, or 0-90) and 
kinact (here 0-1) has been depicted. Values with bars pointing downwards refer to literature 
data, while bars pointing upwards refer to own determinations. Estimates by using the here 
proposed method are based on experimental data from CYP inhibition assays using 
fluorescent substrates described in section 2. Literature data are based on human liver 
microsomes. Units: KI in µM and kinact in min−1.  
 
Figure 1 : Illustration of the influence of different combinations of KI and kinact on the time 
dependence of the IC50. Given a series of IC50 values over time, this in turn allows to 
determine the KI and kinact values by a least squares fit using Eq. (23). 
Figure 2: Principle procedure to obtain KI and kinact values from time-dependent CYP 
inhibition measurements. A. Measurement of inhibition curves at several time points during 
incubation of test compound with enzyme and substrate. Irreversible inhibitors are 
characterized by a time-dependent left shift of the curve as indicated by the arrow. B. Plot of 
IC50 values against incubation time. C and D. Fitting of the model to the IC50 values (e.g. by 
using XLfit) to obtain estimates of Ki and kinact. 
 
Figure 3: Validation of equation (23) and comparison with the relation derived in (Maurer et 
al., 2000). Left: Using equation (19), product formulation over 30 minutes was simulated with 
increasing concentrations of a mechanism-based inhibitor from 0 µM (top) to 9 µM (bottom). 
The parameters Vmax, Km. KI, S and kinact were set to 100 µM/min, 2.5 µM, 2.5 µM, 5 µM, and 
0.5 min-1, respectively (as in Maurer et al.). Right: Comparison of theoretical IC50 values 
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(solid line) with predictions resulting from the herein proposed relation eq. (23) (circles) and 
the alternative relation (eq. (B3) in Maurer et al. 2000)  (squares). 
 
Figure 4: Measured inhibition curves for the seven mechanism-based CYP inhibitors 
(including replicates) with different inhibitor concentrations and at different points in time. 
IC50 values have been obtained for each point in time by fitting a dose-response model with 
variable hill parameter to the data (curves). The obtained IC50 values have been used 
subsequently to estimate KI and kinact values for each inhibitor. 
 
Figure 5: Illustrative time-dependent IC50 values from CYP P450 inhibition experiments for 
seven different mechanism-based inhibitors of CYP isoforms 3A4 and 1A2. IC50 values have 
been determined at different points in time. For each set of IC50 values a curve is fitted by 
using the here developed central relation (23), which represents a specific KI and kinact value 
with goodness of fit given as normalized root mean square error (RMSE). The obtained 
values are listed in Table 1. IC50 values are given in µM. Each plot is an example of up to 
four individual experiments. 






